JP2025501473A - エンジニアリングされたCas12bエフェクタータンパク質及びその使用方法 - Google Patents

エンジニアリングされたCas12bエフェクタータンパク質及びその使用方法 Download PDF

Info

Publication number
JP2025501473A
JP2025501473A JP2024534426A JP2024534426A JP2025501473A JP 2025501473 A JP2025501473 A JP 2025501473A JP 2024534426 A JP2024534426 A JP 2024534426A JP 2024534426 A JP2024534426 A JP 2024534426A JP 2025501473 A JP2025501473 A JP 2025501473A
Authority
JP
Japan
Prior art keywords
cas12b
engineered
amino acid
nuclease
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024534426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501473A5 (cg-RX-API-DMAC7.html
Inventor
李偉
周▲き▼
陳陽燦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Zoology
Institute for Stem Cell and Regenerative Medicine
Original Assignee
Institute of Zoology
Institute for Stem Cell and Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Zoology, Institute for Stem Cell and Regenerative Medicine filed Critical Institute of Zoology
Publication of JP2025501473A publication Critical patent/JP2025501473A/ja
Publication of JP2025501473A5 publication Critical patent/JP2025501473A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2024534426A 2021-12-09 2022-12-09 エンジニアリングされたCas12bエフェクタータンパク質及びその使用方法 Pending JP2025501473A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/136761 2021-12-09
CN2021136761 2021-12-09
PCT/CN2022/137920 WO2023104185A1 (en) 2021-12-09 2022-12-09 Engineered cas12b effector proteins and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2025501473A true JP2025501473A (ja) 2025-01-22
JP2025501473A5 JP2025501473A5 (cg-RX-API-DMAC7.html) 2025-12-17

Family

ID=86686936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024534426A Pending JP2025501473A (ja) 2021-12-09 2022-12-09 エンジニアリングされたCas12bエフェクタータンパク質及びその使用方法

Country Status (5)

Country Link
US (1) US20250051742A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444875A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025501473A (cg-RX-API-DMAC7.html)
CN (2) CN118339285A (cg-RX-API-DMAC7.html)
WO (1) WO2023104185A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022040909A1 (en) * 2020-08-25 2022-03-03 Institute Of Zoology, Chinese Academy Of Sciences Split cas12 systems and methods of use thereof
WO2025067403A1 (zh) * 2023-09-28 2025-04-03 上海天泽云泰生物医药有限公司 用于治疗血红蛋白疾病的组合物和方法
TW202521691A (zh) * 2023-10-06 2025-06-01 美商藍岩醫療公司 經工程化之v型rna可程式核酸內切酶及其用途
CN117487778A (zh) * 2023-10-31 2024-02-02 江南大学 一种全新的基于CRISPR-Cas12b的碱基编辑器的构建及其应用
WO2025096367A1 (en) * 2023-11-03 2025-05-08 University Of Florida Research Foundation, Inc. Thermostable and/or charge-engineered cas12a variants for nucleic acid detection
CN120330162A (zh) * 2023-12-06 2025-07-18 尧唐(上海)生物科技有限公司 一种Cas蛋白、包含其的CRISPR-Cas系统及其应用
WO2026008077A1 (en) * 2024-07-05 2026-01-08 Shanghai Vitalgen Biopharma Co., Ltd. Modified grna for gene editing using crispr/cas system
WO2026060637A1 (en) * 2024-09-20 2026-03-26 Shanghai Vitalgen Biopharma Co., Ltd. Engineered mrna for gene editing using crispr/cas12b

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020033601A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
JP2021512590A (ja) * 2017-12-27 2021-05-20 インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ ゲノム編集のためのシステム及び方法
CN113151215A (zh) * 2021-05-27 2021-07-23 中国科学院动物研究所 工程化的Cas12i核酸酶及其效应蛋白以及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3765615T3 (pl) * 2018-03-14 2023-11-13 Arbor Biotechnologies, Inc. Nowe enzymy i układy crispr ukierunkowane na dna
US20210292747A1 (en) * 2018-07-27 2021-09-23 The Regents Of The University Of Colorado, A Body Corporate Engineered chimeric nucleic acid guided nucleases compositions, methods for making, and systems for gene editing
EP3861112A4 (en) * 2018-10-04 2022-09-21 The Regents of the University of Colorado, A Body Corporate ENGINEERED CHIMERIC NUCLEIC ACID-GUIDED NUCLEAR CONSTRUCTS AND THEIR USES
CN114829595B (zh) * 2019-10-17 2026-05-29 成对植物服务股份有限公司 Cas12a核酸酶的变体及其制备方法和用途
WO2021178934A1 (en) * 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
CN113308451B (zh) * 2020-12-07 2023-07-25 中国科学院动物研究所 工程化的Cas效应蛋白及其使用方法
JP2024522112A (ja) * 2021-05-27 2024-06-11 中国科学院動物研究所 エンジニアリングされたCas12iヌクレアーゼ、エフェクタータンパク質及びその用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021512590A (ja) * 2017-12-27 2021-05-20 インスティテュート オブ ズーオロジー、チャイニーズ アカデミー オブ サイエンシーズ ゲノム編集のためのシステム及び方法
WO2020033601A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Novel cas12b enzymes and systems
CN113151215A (zh) * 2021-05-27 2021-07-23 中国科学院动物研究所 工程化的Cas12i核酸酶及其效应蛋白以及用途

Also Published As

Publication number Publication date
CN118339285A (zh) 2024-07-12
CN116254246B (zh) 2025-09-23
CN116254246A (zh) 2023-06-13
US20250051742A1 (en) 2025-02-13
EP4444875A1 (en) 2024-10-16
WO2023104185A1 (en) 2023-06-15
EP4444875A4 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
CN115851665B (zh) 工程化的Cas12i核酸酶及其效应蛋白以及用途
CN113308451B (zh) 工程化的Cas效应蛋白及其使用方法
US20250051742A1 (en) Engineered cas12b effector proteins and methods of use thereof
KR102935609B1 (ko) 유전자 편집을 위한 cpf1-관련 방법 및 조성물
US20240425830A1 (en) Engineered cas12i nuclease, effector protein and use thereof
KR20210056329A (ko) 신규 cas12b 효소 및 시스템
WO2022040909A1 (en) Split cas12 systems and methods of use thereof
Narayanavari et al. Sleeping Beauty transposition: from biology to applications
JP2024041866A (ja) 強化されたhATファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法
US12097220B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
WO2022120520A1 (en) Engineered cas effector proteins and methods of use thereof
JP7770447B2 (ja) タウの播種または凝集の遺伝的修飾因子を同定するためのcrispr/casスクリーニングプラットフォーム
US20200032251A1 (en) Stem loop rna mediated transport of mitochondria genome editing molecules (endonucleases) into the mitochondria
WO2023138617A1 (zh) 工程化的CasX核酸酶、效应蛋白及其用途
HK40094999A (en) Engineered cas12b effector proteins and methods of use thereof
HK40094999B (zh) 工程化cas12b效应蛋白及其使用方法
HK40109303A (en) Engineered cas12i nuclease, effector protein and use thereof
US20250135032A1 (en) Crispr methods for correcting bag3 gene mutations in vivo
HK40054104B (en) Engineered cas12i nuclease as well as effector protein and use thereof
HK40054104A (en) Engineered cas12i nuclease as well as effector protein and use thereof
HK40099049A (en) Engineered cas effector proteins and methods of use thereof
Peddle Development of all-in-one CRISPR/Cas9 and CRISPRi AAV constructs to treat autosomal dominant retinitis pigmentosa

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251209

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260714